Details of the Drug Combination

General Information of Drug Combination (ID: DC3CX2X)

Drug Combination Name
Ethambutol Azithromycin
Indication
Disease Entry Status REF
Mycobacterium Avium Complex Phase 2 [1]
Component Drugs Ethambutol   DMR87LC Azithromycin   DMS6UOE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ethambutol
Disease Entry ICD 11 Status REF
Pulmonary tuberculosis 1B10.Z Approved [2]
Ethambutol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Arabinosyltransferase C (MycB embC) TT1Q8GP EMBC_MYCTU Inhibitor [6]
------------------------------------------------------------------------------------
Ethambutol Interacts with 16 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Activity [7]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Decreases Activity [7]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Decreases Activity [7]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Decreases Activity [7]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [8]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Secretion [9]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [10]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Increases Expression [10]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Increases Expression [10]
Granzyme B (GZMB) OTPPVIRS GRAB_HUMAN Increases Secretion [9]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [10]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Decreases Expression [10]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Secretion [9]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Increases Expression [10]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Increases Expression [8]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DOT(s)
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [3]
Bronchitis CA20 Approved [4]
Chancroid N.A. Approved [3]
Mycoplasma pneumoniae pneumonia N.A. Approved [3]
Staphylococcus aureus infection N.A. Approved [3]
Streptococcal pneumonia N.A. Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Pneumonia caused by chlamydia N.A. Investigative [3]

References

1 ClinicalTrials.gov (NCT03672630) Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Azithromycin FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
5 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
6 The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46.
7 Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett. 2014 Aug 17;229(1):33-40.
8 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
9 Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury. Chem Res Toxicol. 2016 Nov 21;29(11):1793-1795. doi: 10.1021/acs.chemrestox.6b00393. Epub 2016 Nov 9.
10 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.